Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Stopped Trial terminated due to business decision, not based on any safety or efficacy concerns.

Conditions

• Non-Small Cell Lung Cancer
• Advanced Solid Tumor
• Metastatic Solid Tumor

Interventions

• DRUG: Inlexisertib
• DRUG: Trametinib
• DRUG: Binimetinib
• DRUG: Sotorasib

Sponsor

Deciphera Pharmaceuticals, LLC